Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track XBIT with free AI briefings, catalyst countdowns, and dilution alerts.

XBIT · XBiotech Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$105M Cash on Hand
69.7mo Cash Runway
Follow XBIT by email Get an email when XBIT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about XBIT, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
514G3 (10 mg/kg) plus standard IV antibiotic… Staphylococcus Aureus Bacteremia Phase 1/2 · NCT02357966 Completed
514G3 (40 mg/kg) plus standard IV antibiotic… Staphylococcus Aureus Bacteremia Phase 1/2 · NCT02357966 Completed
Natrunix Rheumatoid Arthritis Phase 2 · NCT05363891 Completed
Phase I: XB2001 1000 mg Pancreatic Cancer Phase 1/2 · NCT04825288 Completed
Phase II: XB2001 1000 mg Pancreatic Cancer Phase 1/2 · NCT04825288 Completed
Vilamakitug Axial Spondyloarthritis Phase 2 · NCT06526377 Not yet recruiting
Hutrukin Pharmacokinetics Phase 1 · NCT05098080 Completed

Also used in these trials (approved or third-party drugs, not XBIT's own candidates): Methotrexate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

XBIT holds $105M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.5M/quarter from operations, an estimated runway of 69.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when XBIT files for a raise →

👥 Who Owns XBIT

Insiders 15.5% Other 5%+ holders 9.9% Institutions (50 holders) 6.7% Public and other holders 67.9%
HolderTypeShares% of sharesAs of
John Simard
Director, 10% owner · +2.77M options
Insider 4,261,690 13.98% 2026-11-03
W. Thorpe McKenzie 5%+ holder (13G) 3,006,259 9.86% 2025-12-31
Thomas Martin Kuendig
Director · +79,115 options
Insider 300,000 0.98% 2025-08-29
Craig Evan Rademaker
Director · +92,104 options
Insider 170,985 0.56% 2025-08-29

Share count 30,487,731 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full XBIT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for XBIT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.